This open-label study randomized @ treatment-nave patients ( @:@ ) with advanced SCCHN into chemoradiation ( CRT nimotuzumab ) or radiation ( RT nimotuzumab ) group by investigator 's discretion ; these were further randomized into CRT + nimotuzumab or CRT and RT + nimotuzumab or RT groups , respectively .